Reuters logo
BRIEF-La Jolla Pharmaceutical Co Announces Initiation Of Clinical Study Of LJPC‑401 In Patients With Beta Thalassemia
December 4, 2017 / 2:13 PM / 7 days ago

BRIEF-La Jolla Pharmaceutical Co Announces Initiation Of Clinical Study Of LJPC‑401 In Patients With Beta Thalassemia

Dec 4 (Reuters) - La Jolla Pharmaceutical Co:

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES INITIATION OF PIVOTAL CLINICAL STUDY OF LJPC-401 IN PATIENTS WITH BETA THALASSEMIA Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below